Related Experiment Video
Updated: Jul 15, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy?
Devanand Sarkar1, Irina V Lebedeva, Pankaj Gupta
1Columbia University Medical Center, Department of Urology, College of Physicians and Surgeons, 630 West 168th Street, New York, NY 10032, USA. ds2039@columbia.edu
Abstract:
An ideal cancer gene therapy would selectively kill cancer cells without harming normal cells and induce multipronged 'bystander' antitumor effects, facilitating eradication of both primary and metastatic tumors. Melanoma differentiation associated gene-7 (mda-7)/interleukin-24 (IL-24) exhibits all of these attributes and more. It induces cancer-selective apoptosis, inhibits angiogenesis, stimulates an antitumor immune response, sensitizes cancer cells to radiation and other modalities of conventional therapies, and exhibits profound 'bystander' activity eliminating both primary and distant tumors in animal models. Moreover, a replication-incompetent adenovirus expressing mda-7/IL-24, Ad.mda-7 (INGN-241), has now undergone evaluation in a Phase I clinical trial for multiple solid tumors, including melanomas, and has demonstrated safety and significant objective clinical activity. Considering these exciting observations, mda-7/IL-24 is being hailed as a 'magic bullet' for cancer gene therapy. This review elaborates on the pleiotropic properties of mda-7/IL-24 and unravels novel aspects of the molecule mandating future studies and expanded clinical applications.
Insights
Melanoma differentiation associated gene-7 (mda-7)/interleukin-24 (IL-24) shows promise as a cancer gene therapy. This therapy selectively targets cancer cells, inhibits tumor growth, and has demonstrated safety and efficacy in clinical trials.
Area of Science:
- Oncology
- Gene Therapy
- Molecular Biology
Background:
- Ideal cancer gene therapy requires cancer-selective cytotoxicity and robust antitumor effects.
- Melanoma differentiation associated gene-7 (mda-7)/interleukin-24 (IL-24) possesses properties beneficial for cancer treatment.
Purpose of the Study:
- To review the pleiotropic properties of mda-7/IL-24.
- To explore novel aspects of mda-7/IL-24 for expanded clinical applications.
Main Methods:
- Review of preclinical and clinical data on mda-7/IL-24.
- Analysis of mda-7/IL-24's mechanisms of action.
Main Results:
- mda-7/IL-24 induces cancer-selective apoptosis and inhibits angiogenesis.
- It stimulates antitumor immunity and sensitizes cancer cells to conventional therapies.
- Ad.mda-7 (INGN-241) demonstrated safety and clinical activity in a Phase I trial.
Conclusions:
- mda-7/IL-24 exhibits significant potential as a 'magic bullet' for cancer gene therapy.
- Further studies are warranted to explore its expanded clinical applications.
